{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:35:45Z","timestamp":1745469345331,"version":"3.40.4"},"reference-count":17,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T00:00:00Z","timestamp":1321488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T00:00:00Z","timestamp":1321488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:p>Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib. At the time of the suboptimal response in patient 1 and the failure in patient 2, we were able to detect the F359I mutation in the BCR-ABL tyrosine kinase domain using DNA sequencing in both patients. Therefore, it was decided to change the therapeutic regimen to dasatinib at a dose of 100 mg once daily in both patients. This change resulted in the achievement of complete cytogenetic remission in patient 1 after 4 months and a major molecular response within 2 and 3 months in both patients. Detection of the F359I mutation in our two cases likely explains the suboptimal response to imatinib in case 1 and the failure in case 2. This implies that in such cases dasatinib should be considered to effectively suppress the mutated clones.<\/jats:p>","DOI":"10.1159\/000333092","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T07:47:05Z","timestamp":1321861625000},"page":"56-59","source":"Crossref","is-referenced-by-count":0,"title":["Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia"],"prefix":"10.1159","volume":"127","author":[{"given":"Mariana","family":"Serpa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabri S.","family":"Sanabani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Enrique","family":"Dorlhiac-Llacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"de Barros Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thays Fernanda","family":"Borges Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199904293401706"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199907153410306"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038%2F243290a0"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038%2F315758a0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.2408149"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053%2Fshem.2003.50034"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.2406902"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2009.25.0779"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.blre.2005.01.008"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2006-01-0092"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa055229"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007%2FBF03195613"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007%2Fs12185-011-0769-z"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2007-03-066936"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2009-08-215939"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2005-12-010132"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.24601"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/333092","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/333092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/333092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:54:58Z","timestamp":1745434498000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000333092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12,20]]}},"URL":"https:\/\/doi.org\/10.1159\/000333092","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"type":"print","value":"0001-5792"},{"type":"electronic","value":"1421-9662"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}